Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know

Novo Nordisk stock fell 3.12% on September 23, 2026, underperforming the S&P 500's 0.76% decline. The stock has dropped 19.03% over the past month, significantly worse than the Medical sector's 3.03% loss. Upcoming earnings are expected to show a 22.55% EPS decline year-over-year, with revenue down 2.18%. The stock holds a Zacks Rank #3 (Hold) rating but trades at a discount valuation with a Forward P/E of 11.2 versus the industry average of 15.93.